{"id":40060,"date":"2025-08-26T13:30:45","date_gmt":"2025-08-26T05:30:45","guid":{"rendered":"https:\/\/flcube.com\/?p=40060"},"modified":"2025-08-26T13:30:45","modified_gmt":"2025-08-26T05:30:45","slug":"inxmed-secures-hk100-m-private-placement-from-trumed-health","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40060","title":{"rendered":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health"},"content":{"rendered":"\n<p>On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/2509:HKG\">HKG: 2509<\/a>) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.<\/p>\n\n\n\n<p><strong>TruMed Health: A Proven Investor in Biopharma<\/strong><br>TruMed Health Innovation Fund is a specialist investment vehicle focused on biopharmaceutical ventures. The fund has a strong track record in Hong Kong, having acted as a cornerstone investor in IPOs for Kelun\u2011Biotech, Bliss Biopharmaceutical, and Ascentage Pharma. Its reputation makes it a bellwether in the region\u2019s healthcare investment landscape.<\/p>\n\n\n\n<p><strong>Strategic Use of Proceeds<\/strong><br>InxMed plans to deploy the capital primarily to optimise its financial structure and accelerate its research\u2011and\u2011development pipeline. The infusion is intended to reinforce the company\u2019s balance sheet and fund the next generation of bispecific antibody programs.<\/p>\n\n\n\n<p><strong>Accelerating a Bispecific Antibody Portfolio<\/strong><br>The raised capital will underpin pre\u2011clinical and clinical studies for several cutting\u2011edge bispecific antibody candidates, including QX027N, QX031N, and QX035N. These projects are positioned to bring new therapeutic options to global markets, strengthening InxMed\u2019s market competitiveness and long\u2011term growth prospects.<\/p>\n\n\n\n<p><strong>Looking Ahead<\/strong><br>With the private placement now closed, InxMed is set to leverage the strengthened financial base to push its R&amp;D agenda forward, aiming to deliver novel bispecific therapies that address unmet medical needs and expand its footprint in the global biopharmaceutical arena.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u5b8c\u6210\u6839\u64da\u4e00\u822c\u6027\u6388\u6b0a\u914d\u552e\u65b0H\u80a1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u5b8c\u6210\u6839\u64da\u4e00\u822c\u6027\u6388\u6b0a\u914d\u552e\u65b0H\u80a1.\"><\/object><a id=\"wp-block-file--media-d5b22643-6ad1-4d03-9759-7ca874780fd4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u5b8c\u6210\u6839\u64da\u4e00\u822c\u6027\u6388\u6b0a\u914d\u552e\u65b0H\u80a1.pdf\">\u5b8c\u6210\u6839\u64da\u4e00\u822c\u6027\u6388\u6b0a\u914d\u552e\u65b0H\u80a1<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/\u5b8c\u6210\u6839\u64da\u4e00\u822c\u6027\u6388\u6b0a\u914d\u552e\u65b0H\u80a1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d5b22643-6ad1-4d03-9759-7ca874780fd4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40068,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[200,2108,20,1239,1796,1832],"class_list":["post-40060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-ascentage-pharma","tag-bliss-biopharmaceutical","tag-finance","tag-hkg-2509","tag-inxmed","tag-kelun-biotech-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InxMed Secures HK$100\u202fM Private Placement from TruMed Health - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40060\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InxMed Secures HK$100\u202fM Private Placement from TruMed Health\" \/>\n<meta property=\"og:description\" content=\"On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40060\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T05:30:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InxMed Secures HK$100\u202fM Private Placement from TruMed Health\",\"datePublished\":\"2025-08-26T05:30:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2604.webp\",\"keywords\":[\"Ascentage Pharma\",\"Bliss Biopharmaceutical\",\"Finance\",\"HKG: 2509\",\"InxMed\",\"Kelun-Biotech Biopharmaceutical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40060#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40060\",\"name\":\"InxMed Secures HK$100\u202fM Private Placement from TruMed Health - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2604.webp\",\"datePublished\":\"2025-08-26T05:30:45+00:00\",\"description\":\"On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40060\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2604.webp\",\"width\":1080,\"height\":608,\"caption\":\"InxMed Secures HK$100\u202fM Private Placement from TruMed Health\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40060#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InxMed Secures HK$100\u202fM Private Placement from TruMed Health\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health - Insight, China&#039;s Pharmaceutical Industry","description":"On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40060","og_locale":"en_US","og_type":"article","og_title":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health","og_description":"On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.","og_url":"https:\/\/flcube.com\/?p=40060","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T05:30:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40060#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40060"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health","datePublished":"2025-08-26T05:30:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40060"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40060#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp","keywords":["Ascentage Pharma","Bliss Biopharmaceutical","Finance","HKG: 2509","InxMed","Kelun-Biotech Biopharmaceutical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40060#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40060","url":"https:\/\/flcube.com\/?p=40060","name":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40060#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40060#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp","datePublished":"2025-08-26T05:30:45+00:00","description":"On August\u202f26,\u202f2025, Hong Kong\u2011listed China-based InxMed (Nanjing) Co., Ltd (HKG: 2509) announced that it has closed a private placement of 5\u202fmillion shares to TruMed Health Innovation Fund LP. Priced at HK$20.0 per share, the transaction raised approximately HK$100\u202fmillion.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40060#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40060"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40060#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp","width":1080,"height":608,"caption":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40060#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InxMed Secures HK$100\u202fM Private Placement from TruMed Health"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40060"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40060\/revisions"}],"predecessor-version":[{"id":40069,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40060\/revisions\/40069"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40068"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}